Prudential Financial’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.08M | Sell |
36,550
-125,685
| -77% | -$5.57M | ﹤0.01% | 1388 |
|
|
2026
Q1 | $4.82M | Sell |
162,235
-57,510
| -26% | -$1.72M | 0.01% | 932 |
|
|
2025
Q4 | $8.4M | Buy |
219,745
+82,134
| +60% | +$2.67M | 0.01% | 691 |
|
|
2025
Q3 | $3.29M | Sell |
137,611
-106,645
| -44% | -$2M | ﹤0.01% | 1131 |
|
|
2025
Q2 | $3.61M | Buy |
244,256
+615
| +0.3% | +$10.2K | ﹤0.01% | 1092 |
|
|
2025
Q1 | $4.37M | Sell |
243,641
-725,500
| -75% | -$14.7M | 0.01% | 898 |
|
|
2024
Q4 | $16.9M | Buy |
969,141
+365,200
| +60% | +$6.46M | 0.02% | 434 |
|
|
2024
Q3 | $8.45M | Buy |
603,941
+168,300
| +39% | +$1.75M | 0.01% | 748 |
|
|
2024
Q2 | $3.58M | Buy |
435,641
+370,380
| +568% | +$2.49M | 0.01% | 1072 |
|
|
2024
Q1 | $503K | Sell |
65,261
-23,800
| -27% | -$201K | ﹤0.01% | 2171 |
|
|
2023
Q4 | $801K | Buy |
+89,061
| New | +$648K | ﹤0.01% | 1934 |
|
|
2022
Q4 | – | Sell |
-14,045
| Closed | -$346K | – | 2703 |
|
|
2022
Q3 | $346K | Buy |
+14,045
| New | +$363K | ﹤0.01% | 2248 |
|
|
2021
Q3 | – | Sell |
-84,064
| Closed | -$1.23M | – | 2627 |
|
|
2021
Q2 | $1.23M | Sell |
84,064
-95,038
| -53% | -$1.87M | ﹤0.01% | 1733 |
|
|
2021
Q1 | $4.47M | Sell |
179,102
-162,180
| -48% | -$4.48M | 0.01% | 1074 |
|
|
2020
Q4 | $9.3M | Sell |
341,282
-103,341
| -23% | -$2.41M | 0.02% | 769 |
|
|
2020
Q3 | $8.21M | Sell |
444,623
-79,583
| -15% | -$1.55M | 0.02% | 743 |
|
|
2020
Q2 | $10.7M | Sell |
524,206
-6,508
| -1% | -$104K | 0.02% | 671 |
|
|
2020
Q1 | $7.74M | Sell |
530,714
-88,610
| -14% | -$1.33M | 0.02% | 742 |
|
|
2019
Q4 | $8.79M | Buy |
619,324
+112,051
| +22% | +$1.43M | 0.01% | 907 |
|
|
2019
Q3 | $5.88M | Buy |
507,273
+254,174
| +100% | +$4.2M | 0.01% | 1041 |
|
|
2019
Q2 | $5.08M | Buy |
253,099
+1,010
| +0.4% | +$19.9K | 0.01% | 1149 |
|
|
2019
Q1 | $5.71M | Buy |
252,089
+2,223
| +0.9% | +$49.1K | 0.01% | 1085 |
|
|
2018
Q4 | $5.65M | Sell |
249,866
-82,650
| -25% | -$2.06M | 0.01% | 1046 |
|
|
2018
Q3 | $9.55M | Sell |
332,516
-38,427
| -10% | -$1.1M | 0.01% | 933 |
|
|
2018
Q2 | $10.1M | Buy |
370,943
+155,520
| +72% | +$4.14M | 0.02% | 916 |
|
|
2018
Q1 | $4.82M | Sell |
215,423
-11,680
| -5% | -$278K | 0.01% | 1188 |
|
|
2017
Q4 | $4.79M | Buy |
227,103
+32,963
| +17% | +$753K | 0.01% | 1180 |
|
|
2017
Q3 | $4.83M | Buy |
194,140
+154,170
| +386% | +$3.39M | 0.01% | 1167 |
|
|
2017
Q2 | $775K | Buy |
+39,970
| New | +$725K | ﹤0.01% | 1923 |
|
Other funds holding TVTX
JT
PA
NAMI
Prudential Financial's TVTX Position: Q2 2026 in Review
Prudential Financial reduced its Travere Therapeutics (TVTX) stake by 77% in Q2 2026, selling an estimated $5.57M and leaving 36,550 shares worth $2.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1388.
Prudential Financial first reported a position in TVTX in Q2 2017 and has held it in 29 quarters since. The position peaked at $16.9M in Q4 2024. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.
- Prudential Financial held 36,550 shares of Travere Therapeutics worth $2.08M as of Q2 2026.
- Prudential Financial sold 125,685 Travere Therapeutics shares in Q2 2026, an estimated $5.57M.
- Travere Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #1388 holding.
- Prudential Financial first reported a position in Travere Therapeutics in Q2 2017 and has held it in 29 quarters since.
- Prudential Financial's Travere Therapeutics position peaked at $16.9M in Q4 2024.
- 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.
Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.